Hyporesponsiveness (immune tolerance) follows vaccination with meningococcal
polysaccharide and many pneumococcal polysaccharide serotypes. Hyporesponsiveness …

A major diagnostic intervention in the consideration of many patients suspected to have
primary immunodeficiency diseases (PIDDs) is the application and interpretation of …

This review focuses on the immune response to non-conjugated and conjugated
polysaccharide vaccines derived from encapsulated pathogens, such as Streptococcus …

Complement factor H (fH), a molecule that downregulates complement activation, binds to
Neisseria meningitidis and increases resistance to serum bactericidal activity. We …

In this dose-ranging study 220 seniors who had received the 23-valent pneumococcal
polysaccharide (PnPS) vaccine at least 5 years prior to enrollment were assigned to receive …

Objective: To determine if acute stress experienced at the time of antigenic challenge
augments the subsequent immune response. Methods: Sixty healthy young adults were …

In 2005, a quadrivalent meningococcal conjugate vaccine was licensed in the United States
for persons aged 11–55 years of age. For children aged 2–10 years with underlying …

Meningococcal disease is a serious and global life-threatening disease. Six serogroups (A,
B, C, W-135, X, and Y) account for the majority of meningococcal disease worldwide …

Background. Repeated immunizations with polysaccharide (PS) vaccines cause
hyporesponsiveness through undefined mechanisms. We assessed the effects of a PS …

Owing to an increase in group C disease, extensive prelicensure studies have been funded
by both the UK Department of Health and vaccine manufacturers. These demonstrated the …